Scientists Crack Nature’s Secret for Building Better Cancer Drugs

Some of medicine’s most valuable cancer drugs are not invented in a lab from scratch; they are borrowed from bacteria, which have spent billions of years perfecting complex molecules. Now scientists at the University of Warwick have uncovered exactly how microbes assemble one important family of these compounds, a discovery that could let chemists design a new generation of cancer therapies with far greater control.

The study, reported by ScienceDaily on July 8, 2026, focused on HDAC inhibitors, a class of drugs that includes romidepsin, marketed as Istodax and approved to treat certain T-cell lymphomas, and the closely related natural product FR-901375. These molecules are built by microbial assembly lines, chains of enzymes that pass a growing molecule from one to the next like workers on a factory floor. The mystery was how the separate enzyme systems recognise and hand off to one another so precisely.

“Now scientists at the University of Warwick have uncovered exactly how microbes assemble one important family of these compounds, a discovery that could let chemists design a new generation of cancer therapies with far greater control.”

The Warwick team, with lead researcher Dr Munro Passmore and Professor Greg Challis of the Monash Warwick Alliance, found the answer in small molecular connectors called “docking domains.” These act as flexible adaptors that let different enzyme modules find their correct partners and cooperate, and they explain how bacteria naturally produce several related drug variants at once. By combining structural biology, biochemistry, genetics and computational modelling, the researchers essentially read the instruction manual for how these medicines are made. “This work finally cracks that code,” the team said. “We’ve identified how the different enzymes communicate and cooperate to produce these drug variants.”

The practical promise is exciting. Because the docking domains behave like modular plugs, scientists could in principle mix and match enzyme parts, a strategy known as combinatorial biosynthesis, to generate entirely new drug variants on demand. That could yield cancer treatments that are more potent, more selective, or gentler in their side effects than what exists today. It is a hopeful illustration of how patiently decoding nature’s own chemistry can hand medicine a powerful new set of building blocks.